Recent Report That Levetiracetam Could Stop the Plaque Formation of Alzheimer’s Disease in Its Earliest Stages Is Further Confirmation of The Positive Effects of AgeneBio’s Novel Therapeutic Approach to Treating Alzheimer’s Disease

– AgeneBio retains exclusive rights to a low-dose, extended- release formulation of levetiracetam designed exclusively for treating cognitive impairment associated with various neurodegenerative indications Baltimore, MD — February 13, 2026 — AgeneBio holds issued patents covering proprietary once-daily extended-release formulations of levetiracetam, including AGB101. The Company’s formulation provides stable drug exposure within a well characterized…